Equity Profile

KNSA

Kiniksa Pharmaceuticals International, plc

Health CareBiotechnology$3.8B

Apr28Tue

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:30 AM EDT

Kiniksa Pharmaceuticals Beats on EPS, Stock Up 1.92%

Metric	Actual	Expected	Surprise
EPS	$0.27	$0.16	+50.00%
Revenue	N/A	$206M	N/A

management commentary, guidance changes, and full analysis available with Pro.

Kiniksa Pharmaceuticals Beats on EPS, Stock Up 1.92%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.27	$0.16	+50.00%
Revenue	N/A	$206M	N/A

Management Commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about the company's performance. They noted the strong EPS results but did not provide specific guidance for future quarters.

Management highlighted the strong performance in EPS as a positive indicator.

They emphasized ongoing efforts to enhance product development.

There was a focus on future opportunities despite not providing specific guidance.

What It Means

Kiniksa Pharmaceuticals reported a strong EPS that exceeded expectations, leading to a 1.92% increase in stock price. The positive surprise in EPS indicates effective cost management or better-than-expected sales. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

Company Snapshot

Kiniksa Pharmaceuticals International, plc (KNSA) operates in the biotechnology sector, focusing on developing innovative therapies for patients with serious diseases. With a market cap of $3 billion, the company plays a significant role in the healthcare landscape, particularly in addressing unmet medical needs.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, and it helps investors gauge performance against expectations.

$0.16

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products, which is crucial for growth.

$206M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q4-2025, Kiniksa reported an EPS of $0.17, which was significantly below the expected $0.29, leading to an 8.21% drop in stock price the following day. The company continues to navigate challenges in meeting market expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Kiniksa to report an EPS of $0.16 and revenue of $206 million for Q1-2026. The market is closely watching how the company addresses previous earnings misses.

Bull Case

If Kiniksa can exceed the EPS estimate and show strong revenue growth, it may signal a turnaround in performance, boosting investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its ability to execute its business strategy, leading to further stock declines.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.16

EPS is a key indicator of the company's profitability and financial health, and it helps investors gauge performance against expectations.

Revenue

$206M

Revenue figures provide insight into the company's sales performance and market demand for its products, which is crucial for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Kiniksa's EPS exceed $0.16, and how will management address past earnings misses?

A positive EPS surprise could restore investor confidence, while another miss could lead to further skepticism about the company's strategy.

What specific revenue figures will Kiniksa report, and how do they align with the $206 million consensus?

Revenue performance is critical for assessing the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Kiniksa's potential for a strong recovery given recent product developments that have not been fully reflected in analyst models.

Supporting Evidence

Kiniksa's recent product pipeline updates suggest potential for higher revenue than currently anticipated.

The significant implied move in options indicates that traders are expecting a more volatile response than historical averages would suggest.

Key Risk

If Kiniksa's revenue comes in significantly above $210 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kiniksa can turn around its recent performance after a series of earnings misses.

Bull Confirmed If

An EPS of $0.20 or higher, coupled with revenue exceeding $210 million, would confirm a strong recovery.

Bear Confirmed If

An EPS below $0.13 or revenue below $201 million would indicate ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±37.04%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±16.1% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

34.3%

Calls (800)P/C Ratio: 0.88Puts (700)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$388,834.32

8,328 sh

2 insiders

Net

$388,834.32

Net selling

Most Active Insiders· 2 open-market trades

CHIEF ACCOUNTING OFFICERMegna Michael R
$309,321.25

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests the stock could rise by an average of 18.59%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 4.58%, reinforcing concerns about the company's ability to meet market expectations.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on strategies to address previous earnings misses.
3Insights into market demand for Kiniksa's therapies and any new partnerships.
4Guidance on future revenue expectations and how they align with analyst estimates.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, and it helps investors gauge performance against expectations.

$0.16

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products, which is crucial for growth.

$206M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Kiniksa to report an EPS of $0.16 and revenue of $206 million for Q1-2026. The market is closely watching how the company addresses previous earnings misses.

Bull Case

If Kiniksa can exceed the EPS estimate and show strong revenue growth, it may signal a turnaround in performance, boosting investor confidence.

Bear Case

Conversely, if the company misses expectations again, it could raise concerns about its ability to execute its business strategy, leading to further stock declines.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.16

EPS is a key indicator of the company's profitability and financial health, and it helps investors gauge performance against expectations.

Revenue

$206M

Revenue figures provide insight into the company's sales performance and market demand for its products, which is crucial for growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Kiniksa's EPS exceed $0.16, and how will management address past earnings misses?

A positive EPS surprise could restore investor confidence, while another miss could lead to further skepticism about the company's strategy.

What specific revenue figures will Kiniksa report, and how do they align with the $206 million consensus?

Revenue performance is critical for assessing the company's growth trajectory and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Kiniksa's potential for a strong recovery given recent product developments that have not been fully reflected in analyst models.

Supporting Evidence

Kiniksa's recent product pipeline updates suggest potential for higher revenue than currently anticipated.

The significant implied move in options indicates that traders are expecting a more volatile response than historical averages would suggest.

Key Risk

If Kiniksa's revenue comes in significantly above $210 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Kiniksa can turn around its recent performance after a series of earnings misses.

Bull Confirmed If

An EPS of $0.20 or higher, coupled with revenue exceeding $210 million, would confirm a strong recovery.

Bear Confirmed If

An EPS below $0.13 or revenue below $201 million would indicate ongoing challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±37.04%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±16.1% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

34.3%

Calls (800)P/C Ratio: 0.88Puts (700)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$388,834.32

8,328 sh

2 insiders

Net

$388,834.32

Net selling

Most Active Insiders· 2 open-market trades

CHIEF ACCOUNTING OFFICERMegna Michael R
$309,321.25

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests the stock could rise by an average of 18.59%, confirming a positive turnaround narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 4.58%, reinforcing concerns about the company's ability to meet market expectations.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline advancements and their expected impact on revenue.
2Management's commentary on strategies to address previous earnings misses.
3Insights into market demand for Kiniksa's therapies and any new partnerships.
4Guidance on future revenue expectations and how they align with analyst estimates.